Search

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

European Affairs

Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

 

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Read more

Introducing YoungEHA: you don’t have to grow old to make a difference

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee. Hearing exciting new research, attending lectures by leaders in the field, and networking are some of the obvious things that are happening during the annual EHA congress.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more